Sotera Health Company (SHC) Stock Price & Analysis

Sotera Health Company (SHC) closed at USD 18.13 on Thursday, October 22, 2026, up 2.03% on the day. The US market is currently closed (pre-market); this is not a live price.

The prior close was USD 17.77; the Oct 22, 2026 session ranged USD 17.51–18.15 on volume of 2,797,513 shares. Market capitalization is $5.17B, with a 52-week range of USD 13.09–19.85 (NMS). Source: Nexqual, retrieved October 23, 2026 at 09:23 UTC.

Also available as compact Markdown for AI agents: nexqual.com/SHC.md

Key facts (SHC)

• Last four reported quarters (through Jun 30, 2026): revenue $1.22B, net income $163M (13.4% margin), free cash flow $113M (SEC filings).
• Valuation: P/E 31.6x (avg 81.8x at the last 3 fiscal year-ends), net debt $1.78B.
• 1 of 80 tracked superinvestors hold SHC (13F, Q2 2026): 0 new, 1 added, 0 reduced, 0 unchanged.
• Insider open-market sales, last ~7 months: 5 Form 4 filings, $797M; 5 not under a Rule 10b5-1 plan ($797M); 0 by opportunistic insiders, 0 by routine insiders (three-year test, Cohen, Malloy & Pomorski 2012).
• Analysts: Buy (mean 2.10 on a 1–5 scale) (10 analysts), mean target USD 22.61 (range 17–25).
• Total return with dividends: 1Y +7.3% vs S&P 500 +14.9%; 5Y -30.3% vs S&P 500 +80.3%.
• Next earnings: 2026-11-03, EPS estimate USD 0.27, revenue estimate $320M.

Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (SHC)

Fiscal years end Dec. EPS is split-adjusted.

Valuation (price ÷ last four quarters, through Jun 30, 2026) (SHC)

P/E 31.6x · P/S 4.3x · EV/Sales 5.7x · P/FCF 45.9x · P/B 7.8x · FCF yield 2.18% · Earnings yield 3.16% · Net debt $1.78B · EV $6.96B

P/E at fiscal year-ends: Dec 2025 64.8x, Dec 2024 87.8x, Dec 2023 92.9x.

Superinvestors (SEC 13F-HR, Q2 2026) (SHC)

1 of 80 tracked investors hold SHC. Each row is the investor's latest 13F; change is vs their prior-quarter share count.

Insider sales (SEC Form 4, open-market, last ~7 months) (SHC)

0 of 5 under a Rule 10b5-1 trading plan (scheduled in advance). Unplanned sales were timed by the insider.

% of holdings sold = shares sold ÷ (shares sold + all holdings the insider reported on that Form 4, direct and through trusts).

Insider type follows Cohen, Malloy & Pomorski (Journal of Finance, 2012). An insider who traded the stock in the same calendar month in each of the past three years is a routine trader; one who traded in each of those years without such a pattern is an opportunistic trader. In their study, trades by opportunistic insiders predicted future returns and trades by routine insiders did not. Counts open-market purchases and sales only (SEC Form 4 codes P and S) by that insider in that company. Not investment advice.

Analysts (SHC)

Consensus Buy (mean 2.10 on a 1–5 scale), 10 analysts; mean target USD 22.61 (low 17, high 25).

Rating changes, last 120 days:

Total return (dividends reinvested) (SHC)

SHC revenue by business segment (quarter ended Jun 30, 2026)

SHC revenue by product line (quarter ended Jun 30, 2026)

SHC revenue by region (fiscal year ended Dec 31, 2025)

As tagged by the company in its SEC 10-Q / 10-K filings (XBRL).

SHC suppliers, customers and competitors (named in its 10-K)

Quoted from the company's 10-K filed Feb 24, 2026.

SHC company outlook (results filed Aug 6, 2026)

• “Together, these strengths position us well to deliver consistent and reliable growth." Shader continued, "Based on our strong first-half performance and confidence in the remainder of the year, we are raising our full-year 2026 outlook.”

Quoted word-for-word from the SEC 8-K results press release.

SHC analyst estimates and revisions

Key Statistics (as of October 23, 2026 at 09:23 UTC)

Technical Analysis (SHC)

Nexqual's technical model rates SHC "NEUTRAL" based on 2 bullish and 3 bearish signals across 127 daily candles, as of October 23, 2026 at 09:23 UTC.

Analyst Ratings (SHC)

Wall Street analysts rate SHC "Buy" based on 10 analysts, with a mean price target of USD 22.61 (range USD 17–25), per Nexqual as of October 23, 2026 at 09:23 UTC.

Earnings (SHC)

Recent Earnings History

Source: Nexqual, October 23, 2026 at 09:23 UTC.

Financials & Fundamentals (SHC)

Source: Nexqual, October 23, 2026 at 09:23 UTC.

Ownership (SHC)

Source: Nexqual, October 23, 2026 at 09:23 UTC.

Leadership (SHC)

Sotera Health Company is led by Alton E. Shader, CEO & Director, per Nexqual as of October 23, 2026 at 09:23 UTC.

Major Backers & Investors (SHC)

Notable institutional backers of Sotera Health Company include Sessa Capital IM, L.P., Darsana Capital Partners, LP, Sculptor Capital LP, according to Nexqual as of October 23, 2026 at 09:23 UTC.

Active Investors

Index Funds (Passive)

Source: Nexqual, October 23, 2026 at 09:23 UTC.

From Sotera Health Company's Latest SEC 10-K Filing (filed 2026-02-24)

Key Strengths & Strategy (as disclosed to the SEC)

• We are a leading global provider of mission-critical end-to-end sterilization solutions, lab testing and advisory services for the healthcare industry.
• Nelson Labs serves approximately 3,000 customers, including many leading medical device manufacturers and pharmaceutical companies.
• We provide end-to-end sterilization as well as microbiological and analytical lab testing and advisory services to help ensure that medical, pharmaceutical and food products are safe for healthcare practitioners, patients and consumers in the United States and around the world.
• We offer a globally integrated platform for our customers in the medical device, pharmaceutical, food safety, and advanced applications markets, with facilities strategically located to be convenient to our customers' manufacturing sites and distribution hubs or routes.

Legal & Regulatory Risks (Item 1A, quoted)

• We may be subject to evolving changes in environmental, health and safety regulations, which may negatively impact our business.
• We may be incorporating AI technologies into our products, services and processes, which may present business, compliance and reputational risks.
• We are subject to complex and rapidly evolving data privacy and security laws and regulations, and any ineffective compliance efforts with such laws and regulations may adversely impact our business.
• Our business is subject to a variety of laws involving the cannabis industry, many of which are unsettled and still developing and which could subject us to claims or otherwise harm our business.

Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.

Peers & Related Stocks

Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 23, 2026 at 09:23 UTC. This page is informational and not investment advice.

For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt